Cargando…
肺癌干性样细胞与耐药
Lung cancer remains the leading cause of cancer-related death world-wide. Therapy resistance and relapse are considered major reasons contributing to the poor survival rates of lung cancer. Accumulated evidences have demonstrated that a small subpopulation of stem-like cells existed within lung canc...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913289/ https://www.ncbi.nlm.nih.gov/pubmed/35224964 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.02 |
_version_ | 1784667403643256832 |
---|---|
collection | PubMed |
description | Lung cancer remains the leading cause of cancer-related death world-wide. Therapy resistance and relapse are considered major reasons contributing to the poor survival rates of lung cancer. Accumulated evidences have demonstrated that a small subpopulation of stem-like cells existed within lung cancer tissues and cell lines, possessing the abilities of self-renewal, multipotent differentiation and unlimited proliferation. These lung cancer stem-like cells (LCSCs) can generate tumors with high effeciency in vivo, survive cytotoxic therapies, and eventually lead to therapy resistance and recurrence. In this review, we would like to present recent knowledges on LCSCs, including the origins where they come from, the molecular features to identify them, and key mechanisms for them to survive and develop resistance, in order to provide a better view for targeting them in future clinic. |
format | Online Article Text |
id | pubmed-8913289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-89132892022-03-25 肺癌干性样细胞与耐药 Zhongguo Fei Ai Za Zhi 综述 Lung cancer remains the leading cause of cancer-related death world-wide. Therapy resistance and relapse are considered major reasons contributing to the poor survival rates of lung cancer. Accumulated evidences have demonstrated that a small subpopulation of stem-like cells existed within lung cancer tissues and cell lines, possessing the abilities of self-renewal, multipotent differentiation and unlimited proliferation. These lung cancer stem-like cells (LCSCs) can generate tumors with high effeciency in vivo, survive cytotoxic therapies, and eventually lead to therapy resistance and recurrence. In this review, we would like to present recent knowledges on LCSCs, including the origins where they come from, the molecular features to identify them, and key mechanisms for them to survive and develop resistance, in order to provide a better view for targeting them in future clinic. 中国肺癌杂志编辑部 2022-02-20 /pmc/articles/PMC8913289/ /pubmed/35224964 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.02 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | 综述 肺癌干性样细胞与耐药 |
title | 肺癌干性样细胞与耐药 |
title_full | 肺癌干性样细胞与耐药 |
title_fullStr | 肺癌干性样细胞与耐药 |
title_full_unstemmed | 肺癌干性样细胞与耐药 |
title_short | 肺癌干性样细胞与耐药 |
title_sort | 肺癌干性样细胞与耐药 |
topic | 综述 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913289/ https://www.ncbi.nlm.nih.gov/pubmed/35224964 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.02 |
work_keys_str_mv | AT fèiáigànxìngyàngxìbāoyǔnàiyào AT fèiáigànxìngyàngxìbāoyǔnàiyào AT fèiáigànxìngyàngxìbāoyǔnàiyào |